

NON-HEALTH-RELATED ASSESSMENT FORM

| REC Form No. | 6 (E2) |
|----------------------|--------|
| Version No: | 02 |
| Date of Effectivity: | |

STUDY PROTOCOL INFORMATION

| Reference Number:1 | |
|---------------------------------|---------------------------------------|
| UPOU IREB Code:2 | |
| Study Protocol Title: | |
| Principal Investigator: | <title, name,="" surname=""></title,> |
| Study Protocol Submission Date: | <dd mm="" yyyy=""></dd> |

INSTRUCTIONS

To the Principal Investigator:

Does your research involve human participants?

- Yes
- No

Please indicate in the space provided below whether or not the specified element is addressed by the informed consent form (ICF). To facilitate the evaluation of the assessment point, indicate the page and paragraph where this information can be found.

To the Primary Reviewer:

Please evaluate how the elements outlined below have been appropriately addressed by the informed consent form (ICF), as applicable, and by confirming the submitted information and putting your comments in the space provided under "REVIEWER COMMENTS." In your comments, ensure that <u>vulnerability, recruitment process</u>, and <u>process of applying research ethics</u> are always assessed in the context of the study protocol and the participant. Finalize your review by indicating your conclusions under "RECOMMENDED ACTION" and signing in space provided for the primary reviewer.

Essential Elements (as applicable to the study)

To be filled out by the PI Indicate if the ICF has the specified element element is found

REVIEWER COMMENTS

- 2. Statement describing the purpose of the study
- 3. Study-related treatments and probability for random assignment
- 4. Responsibilities of the participant

Statement that the study involves research
 Statement describing the purpose

¹ To be issued upon RPC registration/submission

² To be issued upon initial processing by UPOU IREC



NON-HEALTH-RELATED ASSESSMENT FORM

| REC Form No. | 6 (E2) |
|----------------------|--------|
| Version No: | 02 |
| Date of Effectivity: | |

| 5. | Expected duration of participation | • | • | | |
|-----|--|---|---|--|-------------|
| 6. | in the study Approximate number of | • | • | | |
| 7. | participants in the study Study aspects that are | • | • | | |
| 0 | experimental | | | | |
| 8. | Reasonably expected benefits; or absence of direct benefit to | • | • | | |
| 9. | participants, as applicable Expected benefits to the | | | | |
| 9. | community or to society, or | | • | | |
| | contributions to scientific knowledge | | | | |
| 10. | Compensation or insurance or | • | • | | |
| | treatment entitlements of the participant in case of study-related | | | | |
| | injury | | | | |
| 11. | Anticipated payment, if any, to the participant in the course of the | • | • | | |
| | study; whether money or other | | | | |
| | forms of material goods, and if so, | | | | |
| 12 | the kind and amount Compensation (or no plans of | | | | |
| 12. | compensation) for the participant | • | • | | |
| | or the participant's family or | | | | |
| | dependents in case of disability or | | | | |
| | death resulting from study-related | | | | |
| -12 | injuries | | | | |
| 13. | Anticipated expenses, if any, to the participant in the course of the | • | • | | |
| | study | | | | |
| 14. | Statement that participation is | • | • | | |
| | voluntary, and that participant may | | | | |
| | withdraw anytime without penalty | | | | |
| | or loss of benefit to which the participant is entitled | | | | |
| 15. | Statement that the records | • | • | | |
| | identifying the participant will be | | | | |
| | kept confidential and will not be | | | | |
| | made publicly available, to the | | | | |
| | extent permitted by law; and that the identity of the participant will | | | | |
| | remain confidential in the event | | | | |
| | the study results are published; | | | | |
| | including limitations to the | | | | |
| | | | | | Page 2 of 4 |



NON-HEALTH-RELATED ASSESSMENT FORM

| REC Form No. | 6 (E2) |
|----------------------|--------|
| Version No: | 02 |
| Date of Effectivity: | |

| investigator's ability to guarantee confidentiality | | | | |
|--|---|---|--|--|
| 16. Statement that the participant or participant's legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to willingness of the participant to continue to participation | • | • | | |
| 17. Statement describing access of participant to the result of the study | • | • | | |
| 18. Statement describing extent of participant's right to access his/her records (or lack thereof vis à vis pending request for approval of non or partial disclosure) | • | • | | |
| 19. Foreseeable circumstances and reasons under which participation in the study may be terminated | • | • | | |
| 20. Sponsor, institutional affiliation of the investigators, and nature and sources of funds | • | • | | |
| 21. Person(s) to contact in the study team for further information regarding the study and whom to contact in the event of study-related injury | • | • | | |
| 22. Statement that the UPOU IREC has approved the study, and may be reached through the following contact for information regarding rights of study participants, including grievances and complaints: | • | • | | |
| Name of UPOU IREC Chair Address: UPOU HQ Email: Tel: Mobile: | | | | |



NON-HEALTH-RELATED ASSESSMENT FORM

| REC Form No. | 6 (E2) |
|----------------------|--------|
| Version No: | 02 |
| Date of Effectivity: | |

| 23. Comprehensibility of language used | | | | | |
|--|--|------------|--|--|--|
| 24. Other comments not addressed by | | | | | |
| items 1-24 | | | | | |
| RECOMMENDED ACTION: | | | | | |
| APPROVE | | | | | |
| MINOR MODIFICATIONS | | | | | |
| MAJOR MODIFICATIONS | | | | | |
| DISAPPROVE | | | | | |
| PENDING, IF MAJOR CLARIFICATIO | NS ARE REQUIRED BEFORE A DECISION O | AN BE MADE | | | |
| JUSTIFICATION FOR RECOMMENDED ACTION | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| PRIMARY REVIEWER Sign | nature | | | | |
| Date: <dd mm="" yyyy=""> Nar</dd> | ne <title name="" surname=""></th><th></th></tr></tbody></table></title> | | | | |